Today, the United States Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have issued a statement recommending a pause in the use of the Johnson & Johnson COVID 19 vaccine out of an abundance of caution.
After administering more than 6.8 million doses of the Johnson & Johnson vaccine (as of April 12), the U.S. CDC and FDA are currently reviewing six reported cases of a rare and severe type of blood clot in individuals who had received the J&J vaccine. All six cases occurred among women between 18 and 48 years, and symptoms occurred 6 to 13 days after receiving the vaccine.
These cases presented with a rare type of blood clot called cerebral venous sinus thrombosis (CVST) combined with low levels of blood platelets (thrombocytopenia). Treatment of this specific type of blood clot differs from the typically administered treatment (heparin, an anticoagulant drug). However, heparin administration may be dangerous in the current situation. Therefore, alternative treatments need to be given.
CDC and FDA will review these cases to assess their potential significance, and until that process is over, they are recommending a pause in the J & J vaccine use out of an abundance of caution.
CDC and FDA have asked the J & J vaccinees to report to their healthcare providers if they develop severe headaches, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination. Healthcare providers will in turn report the adverse events to the Vaccine Adverse Event Reporting System (VAERS).
Ref: Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine
Link: https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
Tags:
A key advisory group of the Food and Drug Administration experts, known as the Vaccines and Related Biological Products Advisory Committee, has ...
In a historic leap for cancer treatment, thousands of patients are set to receive cutting-edge cancer vaccines, marking the beginning of a new era in ...
In this article, we analyze four recent articles published in Aug-Sept 2020 on the genetic diversity of SARS-CoV-2 and the potential therapeutic targets ...
The measured efficacy/ effectiveness of the vaccine is only a guide for approval and not a benchmark for claiming superiority of one vaccine over another.
LONDON, UK: The UK has become the first country in the world to approve a clinically tested COVID-19 vaccine after the Medicines and Healthcare products ...
Although most individuals recover completely from COVID-19 within a few weeks, some continue to experience symptoms after their initial recovery — even ...
LEIPZIG, Germany: UK health authorities have administered the first doses of the SARS-CoV-2 vaccine developed by Pfizer and BioNTech, and public health ...
The US Food and Drug Administration has granted 'Emergency Use Authorization (EUA)' for Gilead Sciences’ antiviral drug remdesivir to treat COVID-19, the ...
We present five studies published till now, which show that a single dose of vaccine may be enough to elicit a robust immune response in people previously ...
MIAMI, US: Yomi, a robot-assisted surgical device developed by the healthcare start-up Neocis, gained FDA clearance for general dental implant procedures in...
Live webinar
Fri. 19 July 2024
5:30 am IST (New Delhi)
Live webinar
Wed. 7 August 2024
3:30 am IST (New Delhi)
Live webinar
Wed. 14 August 2024
4:30 am IST (New Delhi)
Live webinar
Wed. 14 August 2024
10:00 pm IST (New Delhi)
Live webinar
Wed. 21 August 2024
6:30 pm IST (New Delhi)
Dr. Jim Lai DMD, MSc(Perio), EdD, FRCD(C)
Live webinar
Thu. 29 August 2024
5:30 am IST (New Delhi)
Live webinar
Mon. 2 September 2024
2:30 pm IST (New Delhi)
To post a reply please login or register